Samsung Biologics Expands Global CDMO Leadership with New BMS Deal Amid Industry Shift

Samsung Biologics Has Been Busy This Year. The South Korean CDMO company recently announced that it has expanded its existing production agreement with Bristol-Myers Squibb (BMS). According to the agreement, Samsung Biologics will provide CDMO services at its latest and largest Plant 4 biomanufacturing facility located in Songdo, South Korea. According to a document, this deal is worth approximately $242 million, or about 1.77 billion RMB.